Lung cancer survival signal

Lung tissue. Credit: Rutgers University

Small cell lung cancer (SCLC) represents up to 25 percent of lung cancer cell deaths and is associated with early metastasis and poor patient survival. Thus, SCLC is in need of better therapeutics and more efficient targeted treatments.

Jonathan Lehman, MD, PhD, Pierre Massion, MD,and colleagues have demonstrated that somatostatin receptor 2 (SSTR2), considered to be a cell growth inhibitor, is highly expressed in SCLC cancer cell lines as well as in primary tumors. However, the authors found that high expression of this molecule has a direct correlation to poor survival rate in SCLC patients. They found that reducing SSTR2 expression results in increased apoptosis and decreased .

The study published in the International Journal of Cancer demonstrates that SSTR2 is a candidate biomarker for poor prognosis in SCLC. Furthermore, SSTR2 signaling is not inhibitory in high-grade malignant tumors and instead appears to serve an important pro-tumor survival signal, thus making SSTR2 a potential therapeutic target for .

More information: Jonathan M. Lehman et al. Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer, International Journal of Cancer (2018). DOI: 10.1002/ijc.31771

Journal information: International Journal of Cancer
Citation: Lung cancer survival signal (2018, December 3) retrieved 13 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Novel oncogenic RET mutation found in small cell lung cancer


Feedback to editors